Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Breast Cancer. 27 results shown below.

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer

[Complete title: Combined Targeted Therapies for Triple Negative Advanced Breast Cancer – A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib]
Principal Investigator: Jennifer Specht, MD
Study Number: 6628
Phase: II

F-18 FES PET in Measuring Hormone Expression in Patients with Primary, Recurrent or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

[Complete title: Serial [F-18] fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy]
Principal Investigator: Hannah Linden, MD
Study Number: 7184
Phase: NA

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

[Complete title: I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)]
Principal Investigator: Larissa Korde
Study Number: 7518
Phase: II

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

[Complete title: Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy with [18F]fluorothymidine (FLT) PET]
Principal Investigator: Hannah Linden, MD
Study Number: 7536
Phase: NA

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

[Complete title: Quantitative Dynamic PET and MRI and Breast Cancer Therapy]
Principal Investigator: Jennifer Specht, MD
Study Number: 7587
Phase: NA

Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

[Complete title: Thrombokinetic Studies of Trastuzumab Emtansine]
Principal Investigator: V.K. Gadi, MD, PhD
Study Number: 7900
Phase: I

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (LDTam)

[Complete title: Low-dose Tamoxifen For Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial]
Principal Investigator: Larissa Korde
Study Number: 7908
Phase: II

revention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

[Complete title: Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer]
Principal Investigator: Larissa Korde
Study Number: 7952
Phase: NA

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

[Complete title: Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)]
Principal Investigator: Hannah Linden, MD
Study Number: 8093
Phase: II

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

[Complete title: A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients]
Principal Investigator: Nora Disis, MD
Study Number: 9140
Phase: I

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

[Complete title: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 9198
Phase: II

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

[Complete title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: 9174
Phase: III

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

[Complete title: Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)]
Principal Investigator: Habib Rahbar
Study Number: E4112
Phase: Pilot

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

[Complete title: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy]
Principal Investigator: Janice Kim, MD
Study Number: NSABP B-51 / RTOG 1304
Phase: III

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

[Complete title: A Phase III, Randomized Clinical Trial Of Standard Adjuvant Endocrine Therapy +/- Chemotherapy In Patients With 1-3 Positive Nodes, Hormone Receptor-Positive And Her2-Negative Breast Cancer With Recurrence Score (RS) Of 25 Or Less. Rxponder: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: S1007
Phase: III

S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer

[Complete title: Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: S1200
Phase: NA

A Safety Study of SGN-LIV1A in Breast Cancer Patients

[Complete title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 20131069
Phase: I

AZD8186 First Time In Patient Ascending Dose Study

[Complete title: A Phase 1, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZ8186 in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC), Squamoous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-Deficient Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZ8186 with Prospectively-validated PTEN-deficient Tumors]
Principal Investigator: Tia Higano, MD
Study Number: 20131275
Phase: I

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

[Complete title: A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer]
Principal Investigator: Hannah Linden, MD
Study Number: 20132066
Phase: II

MSB0010718C in Solid Tumors

[Complete title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications]
Principal Investigator: Nora Disis, MD
Study Number: 20132079
Phase: I

A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer

[Complete title: A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzmab Plus Pertuzumab Plus Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer]
Principal Investigator: V.K. Gadi, MD, PhD
Study Number: 20140740
Phase: III

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

[Complete title: A Phase 1, Dose Escalation Study of PF-06664178 in Patients with Locally Advanced or Metastatic Solid Tumors]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20141074
Phase: I

A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

[Complete title: An Open-Label, Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer]
Principal Investigator: Hannah Linden, MD
Study Number: 20141791
Phase: I

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Posivie Solid Tumors

[Complete title: Phase 1, Two-Part, Multiple Ascending Dose Study of Anti-HER2 Fcab FS102 in Breast, Gastric, and Other Solid Tumors]
Principal Investigator: Gabriela Chiorean
Study Number: 20142312
Phase: I

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

[Complete title: A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20150466
Phase: I

Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts

[Complete title: Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women with Dense Breasts]
Principal Investigator: Constance Lehman, MD, PhD
Study Number: 8159
Phase: NA

A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 20140453]
Principal Investigator: Seth Pollack
Study Number: 9079
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials